Gennex Laboratories Q2 Profit Falls 26% as Revenue Rises 4%

Gennex Laboratories Limited reported standalone net profit of ₹3.35 crore for the quarter ended September 30, 2026, down 26.1% year-on-year, while revenue increased 3.7% to ₹32.52 crore. The Board approved the unaudited Q2 FY27 results on November 14, 2026, alongside changes to its board committees.

What did Gennex Laboratories report for Q2 FY27?

Gennex Laboratories reported mixed standalone financial performance in the September 2026 quarter, with higher revenue but lower profit. Revenue from operations rose to ₹32.52 crore from ₹31.37 crore in the corresponding quarter of the previous financial year. Net profit declined to ₹3.35 crore from ₹4.53 crore.

The disclosed figures show that revenue growth did not translate into comparable profit growth during the quarter. The company’s standalone operating margin was reported at 9.96%, compared with 13.48% in Q2 FY26, a decline of 3.52 percentage points. Expenditure was ₹28.96 crore, up 10.8% year-on-year, compared with revenue growth of 3.7%.

For the half year ended September 30, 2026, standalone net profit was ₹7.31 crore, against ₹8.68 crore in the corresponding period a year earlier. The company also reported total standalone assets of ₹294.34 crore, compared with ₹273.82 crore in the prior-year comparable period.

What happened at the November 14 board meeting?

The Board of Directors approved Gennex Laboratories’ unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. It also approved the Statement of Assets and Liabilities and the Statement of Cash Flows included with the financial results.

The board meeting was held on November 14, 2026. The approval formalised the company’s second-quarter financial disclosure for FY27 and provided shareholders with both standalone and consolidated performance data. The filing did not attribute the change in profitability to a specific operational or market factor.

Along with the financial results, the board reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee. It also dissolved the Rights Issue Committee. These are governance-related actions and are separate from the reported quarterly operating performance.

How did consolidated results compare with standalone performance?

Gennex Laboratories reported consolidated total income of ₹44.04 crore in Q2 FY27, compared with ₹39.30 crore a year earlier. Consolidated profit before tax was ₹5.13 crore, against ₹6.06 crore in Q2 FY26, while net profit was ₹4.87 crore compared with ₹5.51 crore.

The consolidated figures indicate a stronger income increase than the standalone revenue movement, but profit still declined from the year-earlier level. Consolidated earnings per share were ₹0.170 for the quarter, compared with ₹0.207 in the corresponding quarter of FY26.

On a quarter-on-quarter basis, the reported consolidated net profit of ₹4.87 crore was above ₹4.67 crore in Q1 FY27. However, the comparison with the year-earlier quarter remains more relevant for assessing the reported annual change in profitability. The source also noted negative operating cash flow during the first half of FY27.

Why did profit decline despite higher revenue?

Gennex Laboratories’ standalone results show that expenses grew faster than revenue in the reported quarter. Standalone expenditure increased 10.8% year-on-year to ₹28.96 crore, while revenue increased 3.7% to ₹32.52 crore. This was accompanied by a reduction in operating margin to 9.96% from 13.48%.

The filing establishes the movement in income, expenditure and profit but does not provide a detailed management explanation for the margin change. Therefore, the results support the conclusion that profitability weakened despite higher revenue, but they do not establish the particular cost categories or business conditions responsible for that change.

The contrast between standalone and consolidated figures is also relevant for investors. Consolidated total income was ₹44.04 crore, higher than standalone revenue of ₹32.52 crore, and consolidated profit was ₹4.87 crore, above standalone profit of ₹3.35 crore. The company’s reported results should therefore be assessed on both bases rather than treating either measure as interchangeable.

What does the update mean for shareholders and operations?

For shareholders, the central Q2 FY27 takeaway is that Gennex Laboratories expanded reported revenue while recording lower year-on-year profit and margin. The standalone profit decline, lower consolidated profit, and fall in consolidated earnings per share point to reduced earnings compared with Q2 FY26.

The increase in standalone total assets to ₹294.34 crore provides balance-sheet context, although the filing does not link the increase to a specific investment, acquisition or operating programme. Similarly, the disclosure of negative operating cash flow in the first half is relevant to cash generation, but the available information does not provide a detailed cash-flow bridge.

The committee reconstitution and dissolution of the Rights Issue Committee are material governance updates disclosed with the financial results. The announcement does not state a new capital-raising plan or provide a further update on a rights issue. Investors will need to rely on subsequent company disclosures for any such development.

Conclusion

Gennex Laboratories delivered higher Q2 FY27 revenue on both the standalone and consolidated measures disclosed, but year-on-year profitability was lower. Standalone net profit fell to ₹3.35 crore from ₹4.53 crore, while consolidated net profit declined to ₹4.87 crore from ₹5.51 crore. The reported margin compression shows that the revenue increase was not sufficient to preserve the prior-year level of earnings.

The next results disclosure will be important for assessing whether expenditure growth, margins and operating cash flow improve after the first half of FY27. Investors should also monitor future board filings for updates following the dissolution of the Rights Issue Committee and the reconstitution of the company’s key governance committees.